Plasma 尾-amyloid peptides levels: A pilot study in bipolar depressed patients

详细信息	查看全文 | 推荐本文 |

• 作者：Armando Piccinni^a ; ¹ ; ^{a.piccinni@med.unipi.it} ; Nicola Origlia^b ; ¹ ; Antonello Veltri^a ; Chiara Vizzaccaro^a ; Donatella Marazziti^a ; Mario Catena-Dell'Osso^a ; Ciro Conversano^a ; Ilenia Moroni^a ; Luciano Domenici^b ; ^c ; Liliana Dell'Osso^a
• 关键词：Bipolar depression ; Dementia ; Cognitive impairment ; Beta-amyloid
• 刊名：Journal of Affective Disorders
• 出版年：2012
• 期刊代码：141_01650327
• 类别：med
• 出版时间：April, 2012
• 卷：138
• 期：1-2
• 页码：160-164
• 文件大小：220 K

摘要

Background

Patients with mood disorders present a great risk for dementia and generally for cognitive decline. Low levels of 尾-amyloid peptide 1-42 (A尾42) and high A尾40/A尾42 ratio have been associated with this risk and have been reported also in geriatric patients suffering from depression. The aim of the present study was to compare the plasma levels of A尾40 and A尾42 in patients with bipolar depression and healthy subjects, and to correlate them with the characteristics of clinical course.

Methods

Levels of A尾40 and A尾42 were measured by using specific ELISA kits in 16 patients with bipolar depression and in 16 control subjects with a negative history for somatic, psychiatric, neurological and substance abuse disorders.

Results

Patients presented significantly lower plasma A尾42 levels and higher A尾40/A尾42 ratio, as compared with control subjects. Moreover, a significant negative correlation was found between A尾42 plasma levels and the duration of the illness, while a positive correlation was detected between the A尾40/A尾42 ratio and the number of affective episodes.

Limitations

The major limitations of the study are the small sample size, the scanty characterization of the illness episodes and the fact that all the patients were under psychopharmacological treatment.

Conclusion

Although further research is necessary to establish firm conclusions, the present data would suggest that changes in plasma levels of different A尾 peptides might represent a useful tool to identify the risk for cognitive decline in bipolar patients.